Interleukin-6 and cachexia in ApcMin/+ mice

被引:225
|
作者
Baltgalvis, Kristen A. [1 ,3 ]
Berger, Franklin G. [2 ,3 ]
Pena, Maria Marjorette O. [2 ,3 ]
Davis, J. Mark [1 ]
Muga, Stephanie J. [4 ]
Carson, James A. [1 ,3 ]
机构
[1] Univ S Carolina, Dept Exercise Sci, Publ Hlth Res Ctr, Integrat Muscle Biol Lab, Columbia, SC 29208 USA
[2] Univ S Carolina, Dept Biol Sci, Columbia, SC 29208 USA
[3] Univ S Carolina, Ctr Colon Canc Res, Columbia, SC 29208 USA
[4] Med Univ S Carolina, Dept Cellular & Mol Pharmacol, Charleston, SC 29425 USA
关键词
cachexia; colorectal cancer; inflammation; polyps; STAT-3;
D O I
10.1152/ajpregu.00716.2007
中图分类号
Q4 [生理学];
学科分类号
071003 ;
摘要
The Apc(Min/+) mouse has a mutation in the Apc tumor suppressor gene and develops intestinal polyps, beginning at 4 wk of age. This mouse develops cachexia by 6 mo, characterized by significant loss of muscle and fat tissue. The purpose of the present study was to determine the role of circulating interleukin-6 (IL-6) and the polyp burden for the development of cachexia in Apc(Min/+) mice. At 26 wk of age, mice exhibiting severe cachectic symptoms had a 61% decrease in gastrocnemius muscle weight, complete loss of epididymal fat, a 10-fold increase in circulating IL-6 levels, and an 89% increase in intestinal polyps compared with mildly cachectic animals. Apc(Min/+)/IL-6(-/-) mice did not lose gastrocnemius muscle mass or epididymal fat pad mass while overall polyp number decreased by 32% compared with Apc(Min/+) mice. Plasmid-based IL-6 overexpression in Apc(Min/+)/IL-6(-/-) mice led to a decrease in gastrocnemius muscle mass and epididymal fat pad mass and increased intestinal polyp burden. IL-6 overexpression did not induce cachexia in non-tumor-bearing mice. These data demonstrate that IL-6 is necessary for the onset of adipose and skeletal muscle wasting in the Apc(Min/+) mouse and that circulating IL-6 can regulate Apc(Min/+) mouse tumor burden.
引用
收藏
页码:R393 / R401
页数:9
相关论文
共 50 条
  • [21] Assessment of Plasma Interleukin-6 as a Biomarker of Pancreatic Cancer-Induced Cachexia
    Ramsey, M. L.
    Talbert, E.
    Conwell, D. L.
    Ahn, D.
    Farren, M. R.
    Hinton, A.
    Dillhoff, M.
    Krishna, S. G.
    Lesinski, G. B.
    Manilchuk, A.
    Pawlik, T. M.
    Rajasekera, P.
    Schmidt, C.
    Bekaii-Saab, T.
    Guttridge, D. C.
    Hart, P. A.
    PANCREAS, 2017, 46 (10) : 1428 - 1428
  • [22] REGULATION OF INTERLEUKIN-6 AND INTERLEUKIN-6 RECEPTOR EXPRESSION
    BAUER, J
    GEROK, W
    BIOLOGICAL CHEMISTRY HOPPE-SEYLER, 1990, 371 (03): : 186 - 186
  • [23] Role of interleukin-6/signal transduction and activator of transcription 3 signalling in cholic acid-induced intestinal carcinogenesis in Apcmin/+ mice
    王斯南
    China Medical Abstracts(Internal Medicine), 2017, 34 (02) : 111 - 112
  • [24] Tendon properties in interleukin-4 and interleukin-6 knockout mice
    Lin, TW
    Cardenas, L
    Soslowsky, LJ
    JOURNAL OF BIOMECHANICS, 2005, 38 (01) : 99 - 105
  • [25] Tendon healing in interleukin-4 and interleukin-6 knockout mice
    Lin, TW
    Cardenas, L
    Glaser, DL
    Soslowsky, LJ
    JOURNAL OF BIOMECHANICS, 2006, 39 (01) : 61 - 69
  • [26] Circulating IL-6 and cancer cachexia in the ApcMin/+ mouse
    Baltgalvis, Kristen A.
    Berger, Franklin G.
    Pena, Maria Marjorette O.
    Carson, James A.
    FASEB JOURNAL, 2007, 21 (06): : A943 - A943
  • [27] The role of interleukin-6 and interleukin-6/interleukin-6 receptor-α complex in the pathogenesis of multiple myeloma
    Barillé, S
    Bataille, R
    Amiot, M
    EUROPEAN CYTOKINE NETWORK, 2000, 11 (04) : 546 - 551
  • [28] Interleukin-6
    Song, MC
    Kellum, JA
    CRITICAL CARE MEDICINE, 2005, 33 (12) : S463 - S465
  • [29] INTERLEUKIN-6
    LOTZ, M
    CANCER INVESTIGATION, 1993, 11 (06) : 732 - 742
  • [30] Impaired neuroglial activation in interleukin-6 deficient mice
    Klein, MA
    Moller, JC
    Jones, LL
    Bluethmann, H
    Kreutzberg, GW
    Raivich, G
    GLIA, 1997, 19 (03) : 227 - 233